Also trades as: 9969.HK (HKSE) · $vol 16M
INCPF OTC
InnoCare Pharma Limited
1W: +19.4%
1M: +19.4%
3M: +19.4%
YTD: -9.8%
1Y: -43.2%
3Y: -43.2%
$1.85
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$2.3B
+127.6% ▲
5Y CAGR: +341.9%
Gross Profit
$2.0B
+131.1% ▲
5Y CAGR: +330.3%
Operating Income
$441M
+183.8% ▲
Net Income
$626M
+242.0% ▲
EPS (Diluted)
$0.36
+238.5% ▲
EBITDA
$556M
+277.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $625M | $739M | $1.0B | $2.3B |
| YoY Growth | +76368.7% | -40.0% | +18.1% | +36.7% | +127.6% |
| Cost of Revenue | $66M | $143M | $128M | $138M | $285M |
| Gross Profit | $977M | $482M | $610M | $871M | $2.0B |
| Gross Margin | 93.7% | 77.1% | 82.6% | 86.3% | 87.6% |
| R&D Expenses | $722M | $639M | $751M | $814M | $849M |
| SG&A Expenses | $345M | $613M | $252M | $311M | $719M |
| Operating Expenses | $1.1B | $1.3B | $1.3B | $1.4B | $1.6B |
| Operating Income | -$181M | -$770M | -$651M | -$526M | $441M |
| Operating Margin | -17.4% | -123.2% | -88.2% | -52.1% | 19.2% |
| Interest Expense | $3M | $17M | $35M | $34M | $54M |
| Income Before Tax | -$20M | -$894M | -$644M | -$453M | $639M |
| Tax Expense | $47M | $0 | $1M | $263K | $11M |
| Net Income | -$65M | -$887M | -$631M | -$441M | $626M |
| Net Margin | -6.2% | -141.8% | -85.5% | -43.7% | 27.2% |
| EPS (Diluted) | $-0.04 | $-0.60 | $-0.37 | $-0.26 | $0.36 |
| EBITDA | -$167M | -$808M | -$517M | -$313M | $556M |
| Shares Outstanding | 1.76B | 1.48B | 1.71B | 1.69B | 1.76B |